NEW HAVEN — A saliva-based test for the coronavirus developed by Yale researchers and used to test National Basketball Association players during the pandemic will soon be available in three more states, according to the university.
The SalivaDirect testing method was granted an emergency use authorization by the U.S. Food and Drug Administration in August.
It is now available through the Yale Pathology Labs, university officials said Friday, and will soon be offered by Access Medical Laboratories, Hennepin County Medical Center , and Mirimus, Inc., making it “available to people in Florida, Minnesota and New York by late September.”
Nathan Grubaugh and Anne Wyllie, assistant professor and associate research scientist, respectively, at Yale School of Public Health, led the development of the new test in recent months, according to a release.
In the release, officials said the new method is “less prone to supply chain bottlenecks, more economical, and less invasive than nasopharyngeal (NP) swabbing, the most common form of testing available currently.”
“After discovering saliva is a promising sample type for SARS-CoV-2 detection, we have made it our mission to develop a testing method that is accurate, affordable, and accessible to all,” Wyllie said, also in the release. “Our hope is that eventually every person that needs a COVID-19 test will be able to get one. Our laboratory partners are instrumental in ensuring schools and other essential institutions can remain open and healthy.”
Grubaugh and Wyllie had discussed the development of the new test with the Register in August.
A representative of the Minnesota Timberwolves vouched for the effectiveness of the test, according to the release. It has been used to test players in the NBA’s bubble, as the league completes its regular season and playoffs.